Addex Therapeutics

ADXN

Addex Therapeutics leverages its proprietary allosteric modulation platform to develop novel therapeutics for neurological and psychiatric disorders. The company's most advanced candidate, dipraglurant, is in Phase 2/3 development for Parkinson's disease dyskinesia, representing a significant unmet medical need. Addex is publicly traded on the SIX Swiss Exchange and Nasdaq, maintaining a focused pipeline with strategic partnerships to advance its research. Their approach aims to create drugs with improved selectivity and fewer side effects compared to traditional orthosteric compounds.

addextherapeutics.com

ADXN · Stock Price

USD 6.51+0.85 (+14.93%)

Market Cap: $8.0M

Historical price data

Market Cap: $8.0MPipeline: 8 drugs (2 Phase 3)Employees: 20-50HQ: Switzerland

Sector Ranking#286 in Small Molecule Drugs #69 in Neuroscience & CNS

AI Company Overview

NeurologyPsychiatry

Technology Platform

Proprietary discovery platform for allosteric modulators of G-protein coupled receptors (GPCRs), focusing on creating novel small molecule drugs with high selectivity and improved safety profiles.

Pipeline

8 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Dipraglurant	Parkinson Disease	Phase 2/3
Dipraglurant + Placebo	Parkinson Disease	Phase 2/3
ADX10059 + ADX10059 + ADX10059 + ADX10059 Matching Placebo	Gastroesophageal Reflux	Phase 2
ADX10059 + ADX10059 Matching Placebo	Gastroesophageal Reflux	Phase 2
ADX10059 + ADX10059 + ADX10059 + ADX10059 Matching Placebo	Migraine	Phase 2

Funding History

Total raised:$88M

PIPE$8MUndisclosedApr 15, 2020

IPO$60MUndisclosedJun 15, 2007

Series A$20MNovartis Venture FundMay 15, 2002

Opportunities

The primary growth opportunity is the successful development and commercialization of dipraglurant for PD-LID, a large market with high unmet need.

Further opportunities exist in expanding dipraglurant into other movement disorders (e.g., blepharospasm) and leveraging the allosteric modulator platform to generate new drug candidates for CNS and other disorders through internal R&D or additional partnerships.

Risk Factors

Key risks include clinical trial failure of the lead asset, dipraglurant, which would significantly devalue the company.

Financial risk is high due to dependence on capital markets for funding late-stage trials.

The company also faces regulatory uncertainty and competition from larger, better-resourced pharmaceutical companies.

Competitive Landscape

Main competitors in PD-LID include Supernus (Gocovri) and other companies developing treatments for dyskinesia. In the allosteric modulator space, competitors include Karuna/BMS and Acadia. Addex differentiates through its specific mGlu5 NAM mechanism for dyskinesia and its early, specialized expertise in mGluR and GPCR allosteric modulation.